NCT06279663 (NSTE-ACSMT) is a NA clinical trial of Revascularization in Coronary Syndrome, Acute, Non-ST Elevation, High Risk Patients, sponsored by Federal State Budgetary Institution National Medical Research Center named after academician E.N. Me.

What drugs are being tested in NCT06279663?

Interventions in NCT06279663: Revascularization.

What condition does NCT06279663 study?

NCT06279663 studies Coronary Syndrome, Acute, Non-ST Elevation, High Risk Patients.

Is NCT06279663 still recruiting?

NCT06279663 is currently recruiting now. Last updated 13 March 2024.

Last reviewed 2024-03-13 · How we verify

NCT06279663: NSTE-ACSMT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Management Tactics for Patients High Risk With Acute Coronary Syndrome Without ST Segment Elevation and Multivessel Coronary Artery Disease

Recruiting now NA Last updated 13 March 2024

What this trial tests

NA trial testing Revascularization in Coronary Syndrome, Acute, Non-ST Elevation, High Risk Patients in 460 participants. Currently enrolling.

Timeline

29 February 2024

Primary endpoint
31 December 2028

31 December 2029

Quick facts

Lead sponsor	Federal State Budgetary Institution National Medical Research Center named after academician E.N. Me
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	460
Start date	29 February 2024
Primary completion	31 December 2028
Estimated completion	31 December 2029
Sites	2 locations across Russia

Drugs / interventions tested

Revascularization

Conditions studied

Coronary Syndrome, Acute, Non-ST Elevation, High Risk Patients — all drugs for Coronary Syndrome, Acute, Non-ST Elevation, High Risk Patients →

Sponsor

Federal State Budgetary Institution National Medical Research Center named after academician E.N. Me

Who can join

18 and older, any sex, with Coronary Syndrome, Acute, Non-ST Elevation, High Risk Patients. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study will include patients with acute coronary syndrome without ST segment elevation and multivessel CA lesion, who are subject to surgical treatment according to KG data (Syntax Score 23 - 32 points with significant damage to the anterior descending artery and/or trunk of the left coronary artery). The patient should be suitable for both CABG and PCI (confirmed by an X-ray surgeon and a cardiac surgeon). An X-ray surgeon and a cardiac surgeon, within the framework of planning the volume of revascularization, strives for the fullest feasible volume. Complete myocardial revascularization (that is, the desire for the absence of hemodynamically significant coronary arteries after revascularization, with a diameter of \> 2.5 mm, that is, residual coronary artery stenosis of no more than 60%). Thus, patients will be randomized into groups in a ratio of 1:1. Each group will need to include 230 patients (a total of 460). In the main group, revascularization will be performed by PCI, in the control group by CABG.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Revascularization

Trials testing the same drug.

NCT06832839 — Study on the Mechanism of Cognitive Impairment in Patients with Moyamoya Disease · recruiting
NCT05644158 — Mitochondrial Function in Peripheral Arterial Disease · NA · unknown
NCT05570019 — Evaluation of Tissue Perfusion in Peripheral Arterial Disease (EVTI-PAD) · unknown
NCT04252950 — Community-based Exercise Following Revascularization for PAD · NA · recruiting
NCT04939038 — Timing of Revascularization in Patients With Diabetic Foot Ulcer and Non-critical Peripheral Artery Disease · NA · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06279663 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Federal State Budgetary Institution National Medical Research Center named after academician E.N. Me
Last refreshed: 13 March 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06279663.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing